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THE ECONOMIC BURDEN OF CHRONIC OBSTRUCTION PULMONARY
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OBJECTIVES: Smoking is one of the leading causes to develop chronic obstruction 
pulmonary disease (COPD). The economic burden of COPD inﬂ icted by smoking 
remains unclear. The goal of this study is to estimate cost of COPD-related health care 
services consumed by the smokers, in comparison with that consumed by the non-
smokers. METHODS: The Markov model was constructed to simulate incidence and
progression of COPD and to estimate cost of health care services consumed by COPD 
patients over a 25-year time period. The analysis was restricted to males aged 50–54
years. The cohort of subjects in the model was derived from the NHANES 2005–06
dataset. Based on the number of cigarette consumption, the subjects were categorized 
into four groups: non-smokers, light smokers, moderate smokers, and heavy smokers. 
COPD severity was classiﬁ ed into three stages, based on GOLD criteria (I, II, III/IV). 
RESULTS: In comparison with the three smoking groups, the non-smoking group had 
the lowest average annual COPD-related health care services cost per person, $821
and the longest average survival period per person, 17.23 years. With the non-smoking
group serving as the baseline group, the incremental COPD-related health care services 
cost of the light smoking group, the moderate smoking group, and the heavy smoking 
group was $546, $681, and $2127 per person, but incremental survival of each group
was 0.01, 0.05, and 0.16 year, respectively. The average annual COPD-related
health care services cost consumed by the non-smokers, the light smokers, the moder-
ate smokers, and the heavy smokers in the age of 50 to 54 years was $146,121,634,
$376,555,801, $413,543,396, and $1,471,262,617, respectively. CONCLUSIONS:
Compared to the non-smokers, the smokers at higher level of risk to COPD caused a 
heavy economic burden to the society.
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HOW MUCH WOULD AMERICA SAVE IF ASTHMA DID NOT EXIST?
Link SB, Nurmagambetov T
Center for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: According to data from the National Health Interview Survey, an 
estimated 22 million Americans had asthma in 2005. Previous estimates of the cost
of asthma are outdated; therefore, there is not a clear understanding of the value of 
resources that are used for asthma care and the loss of productivity to society. This
study seeks to estimate the cost of asthma to society in 2006 through evaluating direct
medical expenditures and indirect costs. METHODS: The expenditure attributable to
asthma for health care events (ofﬁ ce based visits, emergency department visits, inpa-
tient stays, outpatient visits, and prescription medications) is estimated using the 
two-step regression technique on 2006 data from the nationally representative Medical 
Expenditure Panel Survey (MEPS). Work and school absentee days attributable to 
asthma are estimated using negative binomial regression and are valued following the
human capital approach. The authors rely on published estimates for the value of the
loss of life from premature death. RESULTS: Using data from 2006, having asthma 
resulted in an estimated additional $1308 (in 2006 dollars) in direct medical expen-
ditures per person with asthma, of which almost half ($734) is attributable to prescrip-
tion medication. Asthma was responsible for an excess of approximately 2.6 school 
days missed per student with asthma and an excess of approximately 1.7 working
days lost per person in the labor force with asthma, costing society an estimated
US$2.3 billion. CONCLUSIONS: This paper updates past estimates of the total cost 
of asthma to society through employing recent data and methods. These estimates
may be used to articulate both the monetary burden of asthma and the savings that 
are achievable when programs aimed at managing asthma are successful at reducing
preventable health care utilization.
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OBJECTIVES: To review literature on the medical costs of COPD exacerbations. 
METHODS: A systematic search of the MEDLINE database from 1998–2008 was
conducted using the search terms COPD, exacerbation, and economic or cost. Selected
conference abstracts were also searched. Articles that contained medical cost data 
related to COPD exacerbations were selected for in-depth review. RESULTS: The 
initial search criteria yielded 184 journal articles. In-depth review was performed on 
13 articles examining health care costs and utilization associated with exacerbations
(conceptually deﬁ ned as sustained worsening of COPD patient’s condition from stable 
state, beyond normal day-to-day variations, with acute onset). These studies were
conducted in eight different countries. The mean estimated costs of exacerbations vary
widely across studies: $115 to $9,060 per exacerbation (2007 US dollars). Hospitaliza-
tion typically was the largest cost driver (58–77% of total exacerbation cost). Cost
was highly correlated with exacerbation severity: severe exacerbations were 7–15
times more expensive than moderate and 47–182 times greater than mild. The wide
variability in these cost estimates reﬂ ected cross-study differences in geographic loca-
tions, patient populations, methodologies for operationally deﬁ ning exacerbations
(e.g., event-based and symptom-based approaches), tools used to identify and measure 
exacerbations (e.g., symptomatic measures and biological measures), and classiﬁ cation 
of exacerbation severity. In addition, the literature shows that patients frequently suf-
fered from unreported exacerbations to health care providers; these may not be cap-
tured in direct cost estimates. CONCLUSIONS: Studies of the direct cost of COPD 
exacerbations show that exacerbations have signiﬁ cant economic impacts. Cost esti-
mates vary widely, and interpretation and application of these cost estimates require
an understanding of the different methodologies used to deﬁ ne, identify, and character-
ize exacerbations.
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OBJECTIVES: To compare the treated disease prevalence, health care costs and 
utilization, and work-loss, of employees who had never smoked as compared to
those who were current smokers. METHODS: Three Thomson MarketScan
Research Databases were used: The Commercial Claims and Encounters and Health 
and Productivity Management (HPM) Databases, providing health care and work-
place productivity data for patients insured commercially, and the MarketScan
Health Risk Assessment (HRA) database. HRA data provided information on smoking
status. Current versus never smokers were compared in terms of treated medical 
conditions, health care cost and utilization, and work-loss using bivariate descriptive 
statistics and regression analyses. Control variables in the regression analyses 
were age, gender, body mass index, health plan capitation, education, income, and
employer characteristics. RESULTS: Current smokers had a signiﬁ cantly higher risk 
for respiratory diseases compared with never smokers (a higher prevalence rate of 
1,420 per 100,000, p  0.01). On average, smokers used 1.81 fewer outpatient services 
per year (from a mean rate of 13.52) (p  0.01), ﬁ lled 0.48 more prescriptions per
year (from a mean rate of 8.63) (p  0.05), and had 0.02 more emergency room visits
per year as compared with those who never smoked (mean number of 0.16) (p  0.01). 
Relative to never smokers, an average smoker had 13.26 more absent hours and 1.47
more short-term disability days per year (the mean number of absence hours was
74.46; the mean of number of short-term disability days was 4.93) (all p values 
0.01). The absence and short-term disability costs of a current smoker was $282.77 
and $158.40 higher per year, respectively, as compared to a never smoker. CONCLU-
SIONS: Compared to never smokers, current smokers had a signiﬁ cantly higher preva-
lence of respiratory diseases, used more prescriptions, had more emergency room 
visits, fewer outpatient services, and incurred more absence hours, short-term disabil-
ity days, and absence costs.
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OBJECTIVES: Evaluate whether one-year total health care expenditure and utilization 
differ between the appropriate therapy and inappropriate therapy for severe asthmatic 
patients in a Medi-Cal population. METHODS: This is a cross-sectional retrospective 
study of asthmatic patients provided care between July 2002 and July 2006 in
the California Medi-Cal program. The study evaluates severe asthmatic patients 
who had at least one hospitalization due to asthma. Patients were followed for
asthma-related health care service use and costs for one year after asthma related 
hospitalization. Patients under treatment with asthma-related medications for other
conditions and/or aged 65 or older were excluded from the sample. Patients 
were classiﬁ ed in two groups: appropriate and inappropriate therapy based on pub-
lished guidelines. Appropriate therapy was deﬁ ned as controller use without daily 
reliever use and inappropriate therapy was deﬁ ned as controller use with daily 
reliever use or no controller use with reliever use. RESULTS: A total of 4728 patients 
were included in the analyses. Multivariate analysis showed that appropriate therapy 
was associated with a 9% reduction in asthma related health care costs compared
with the inappropriate therapy group (p-value 0.0287). Gender (Male) and race 
(white and asian compared to Hispanic) were also associated with decreased total 
health care expenditures. Moreover, patients who received appropriate therapy are
less likely (34% less) to have an asthma-related acute exacerbation (OR  0.664, 
p-value  0.0001) compared to those with inappropriate therapy. CONCLUSIONS:
The ﬁ ndings suggest that the use of appropriate therapy improves the asthma-related 
health outcomes for severe asthmatic patients. Patients in the appropriate therapy 
group are less costly and less likely to be hospitalized or have an emergency visit 
compared to patients who had inappropriate therapy. Despite years of national efforts 
and effective medications, there is substantial room for improvement and there con-
tinues to be excess health care utilization and expenditures for some severe asthma
patients.
